--- title: "PureTech Health plc (PRTCY.US)" type: "Symbol" locale: "zh-CN" url: "https://longbridge.com/zh-CN/quote/PRTCY.US.md" symbol: "PRTCY.US" name: "PureTech Health plc" industry: "生物技术" datetime: "2026-05-30T05:29:56.490Z" locales: - [en](https://longbridge.com/en/quote/PRTCY.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/PRTCY.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/PRTCY.US.md) --- # PureTech Health plc (PRTCY.US) | 项目 | 详情 | |------|--------| | 行业 | 生物技术 | | 交易所 | US Market | | 官网 | [www.puretechhealth.com](https://www.puretechhealth.com) | ## 关键驱动因素 > *AI 分析的影响该股票表现的关键因素* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Longbridge 独家多因子评级模型* > 更新时间: 2026-05-29T04:30:15.000Z **综合: D (0.73)** **行业**: 生物技术 | 指标 | 数值 | |--------|-------| | 行业排名 | 242 / 390 | | 行业中位数 | C | | 行业均值 | C | - **风格**: 价值型 - 公司主要业务处在成熟期的股票。 - **规模**: 小盘型 - 公司经营有较高的成长性和波动性,易于获得较高的投资收益。 **综合评分**: D #### 风格得分 评分: | 指标 | 数值 | 评级 | |-----------|-------|--------| | 营业收入同比 | -3.50% | | | 净利润同比 | -305.08% | | | 市净率 | 1.41 | | | 股息率 | 0.00% | | #### 规模得分 评分: | 指标 | 数值 | 评级 | |-----------|-------|--------| | 市值 | 439369832.95 | | | 营业收入 | 4659000.00 | | #### 多维评分 评分: D | 指标 | 数值 | 评级 | |-----------|-------|--------| | 净资产收益率(ROE) | -30.20% | E | | 净利率 | -2355.42% | E | | 毛利率 | -1111.74% | E | | 营业收入同比 | -3.50% | D | | 净利润同比 | -305.08% | E | | 总资产同比 | -11.27% | E | | 净资产同比 | -25.07% | E | | 现金流净利率 | 77.58% | C | | 运营现金流同比 | -3.50% | D | | 资产周转率 | 0.01 | E | | 资产负债率 | 42.83% | C | ```chart-data:radar { "title": "Longbridge Financial Score - PureTech Health plc", "chart_type": "radar", "dimensions": [ { "name": "风格得分", "grade": "", "indicators": [ { "name": "营业收入同比", "value": "-3.50%", "rating": "" }, { "name": "净利润同比", "value": "-305.08%", "rating": "" }, { "name": "市净率", "value": "1.41", "rating": "" }, { "name": "股息率", "value": "0.00%", "rating": "" } ] }, { "name": "规模得分", "grade": "", "indicators": [ { "name": "市值", "value": "439369832.95", "rating": "" }, { "name": "营业收入", "value": "4659000.00", "rating": "" } ] }, { "name": "多维评分", "grade": "D", "indicators": [ { "name": "净资产收益率(ROE)", "value": "-30.20%", "rating": "E" }, { "name": "净利率", "value": "-2355.42%", "rating": "E" }, { "name": "毛利率", "value": "-1111.74%", "rating": "E" }, { "name": "营业收入同比", "value": "-3.50%", "rating": "D" }, { "name": "净利润同比", "value": "-305.08%", "rating": "E" }, { "name": "总资产同比", "value": "-11.27%", "rating": "E" }, { "name": "净资产同比", "value": "-25.07%", "rating": "E" }, { "name": "现金流净利率", "value": "77.58%", "rating": "C" }, { "name": "运营现金流同比", "value": "-3.50%", "rating": "D" }, { "name": "资产周转率", "value": "0.01", "rating": "E" }, { "name": "资产负债率", "value": "42.83%", "rating": "C" } ] } ] } ``` ## 估值分析 | 指标 | 当前值 | 行业排名 | 最高 | 中位 | 最低 | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -4.10 | 341/390 | - | - | - | | PB | 1.44 | 125/390 | - | - | - | | PS (TTM) | 96.69 | 251/390 | - | - | - | | Dividend Yield | 0.00% | - | - | - | - | ## 同业比较 | 排名 | 名称 | 盈利 | 成长 | 运营 | 财务安全 | 现金流 | 评级 | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A | | 03 | Rigel制药 (RIGL.US) | A | A | B | A | B | A | | 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A | | 05 | OpGen (OPGN.US) | B | A | A | A | B | A | ## 参考链接 - [公司概况 — 简介、高管、股东、业务构成](https://longbridge.com/zh-CN/quote/PRTCY.US/overview.md) - [财务报表 — 利润表、资产负债表、现金流、分红方案](https://longbridge.com/zh-CN/quote/PRTCY.US/norm.md) - [相关新闻](https://longbridge.com/zh-CN/quote/PRTCY.US/news.md) - [公告 — 公司公告与监管文件](https://longbridge.com/zh-CN/quote/PRTCY.US/filings.md) --- > **免责声明: 本文仅供参考,不构成任何投资建议。**